New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 28, 2013
09:26 EDTAFAM, PFE, BIIB, DNDN, GTIV, ABFS, ACI, ACN, LHCG, AMED, SNY, MCP, BBRYOn The Fly: Pre-market Movers
HIGHER: Dendreon (DNDN), up 9.8% after getting positive EU opinion for Provenge drug... Arkansas Best (ABFS), up 10% after ABF Freight System employees represented by Teamsters ratify five-year national labor agreement... Molycorp (MCP), up 7.8% after SEC completes investigation with no enforcement action recommended... Arch Coal (ACI), up 8.9% after announcing will sell non-core Utah operations to Bowie Resources for $435M... Biogen (BIIB), up 5.8% after the European Medicines Agency granted Sanofi's multiple sclerosis drug Aubagio "new active substance" status. Sanofi, which also received a positive CHMP opinion for Lemtrada, up 1.5%... Pfizer (PFE), up 1% after boosting share buyback program by $10B. DOWN AFTER EARNINGS: BlackBerry (BBRY), down 23%... Accenture (ACN), down 9%... Nike (NKE), down 0.8%. ALSO LOWER: Home health agencies, including Amedisys (AMED), down 21%, Gentiva Health (GTIV), down 16%, Almost Family (AFAM), down 13%, and LHC Group (LHCG), down 12%, after the Centers for Medicare & Medicaid Services proposed 2014 reimbursement cuts.
News For BBRY;ACN;DNDN;MCP;ACI;BIIB;SNY;ABFS;PFE;AMED;GTIV;AFAM;LHCG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 21, 2015
14:48 EDTSNYRegeneron primary driver remains Praluent, says Piper Jaffray
Piper Jaffray noted that Regeneron (REGN) shares are at all-time highs after the company and partner Sanofi reported Phase IIb data on Dupilumab and Phase III data on Sarilumab. However, the firm believes the primary driver for Regeneron remains Praluent and firm expects launch costs to outstrip sales growth. Piper acknowledges Regeneron has "one of the richest pipelines in all of biotech," but it sees risk around Amgen's (AMGN) patent suit and keeps its Neutral rating and $484 price target on the stock.
10:58 EDTBIIBDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:37 EDTPFEPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
05:15 EDTSNYRegeneron, Sanofi announce positive topline results from sarilumab Phase 3 study
Subscribe for More Information
May 20, 2015
07:46 EDTPFEDeutsche Bank positive on potential Pfizer, GSK merger
Deutsche Bank analyst Gregg Gilbert believes a large foreign deal for Pfizer (PFE) may make sense and says a buyout of GlaxoSmithKline (GSK) could be "materially" accretive to earnings while improving the company's tax situation over time. Gilbert assumes a $60 per share buyout price for GlaxoSmithKline in a research note this morning titled "Introducing 'PfizerKline'". The stock closed yesterday up 2c to $44.68. Gilbert reiterates a Buy rating on Pfizer with a $41 price target. Shares ended yesterday up 23c to $34.21.
May 19, 2015
08:37 EDTBBRYBlackBerry software showing encouraging signs, says RBC Capital
RBC Capital says it's seeing encouraging signs regarding the sales of BlackBerry's software to regulated sectors, including government ,financials, and healthcare. The firm says that the company's mobile device management system, BES 12, is adding customers, while its resellers are getting more comfortable selling its software and sales of its technology solutions products are beating its guidance. RBC slashed its hardware sales estimates for the company and expects its Q1 revenue to come in well below expectations as a result, but adds that software has become the company's focus. It keeps an $11 price target and Sector Perform rating on the shares.
06:55 EDTPFE, SNYGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
06:29 EDTBBRYBlackBerry CEO says smartphone business will be profitable again, BI reports
Subscribe for More Information
06:21 EDTAMEDAmedisys management to meet with SunTrust
Meeting to be held in Boston on May 20 hosted by SunTrust.
May 18, 2015
12:34 EDTSNYRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
06:58 EDTPFEActavis CEO says chances of Pfizer offer are 'unlikely', Financial Times says
Actavis (ACT) CEO Brent Saunders said the chances of Pfizer (PFE) making an offer are "incredibly unlikely," reports the Financial Times. Saunders said he has heard the gossip that Actavis could become a takeover target for a larger group, but he spends "zero time thinking about it." Reference Link
05:50 EDTBBRYStocks with implied volatility movement; BBRY MNKD
Stocks with implied volatility movement; BlackBerry (BBRY) 55, MannKind (MNKD) 75 according to iVolatility.
05:27 EDTACNAccenture to acquire Javelin Group, terms not disclosed
Subscribe for More Information
May 17, 2015
14:59 EDTSNYL'Oreal CEO 'ready' to sell Sanofi stake if needed, Barron's says
Subscribe for More Information
May 15, 2015
15:26 EDTBBRYBlackBerry calls active amid rumor of Microsoft investigation of potential bid
Subscribe for More Information
15:00 EDTBBRYBlackBerry rises amid rumor of Microsoft investigation of potential bid
Shares of BlackBerry (BBRY) are higher in afternoon trading after Ben Harrington's Betaville blog said Microsoft (MSFT) is said to have requested Deutsche Bank (DB) and Goldman Sachs (GS) examine whether the company should acquire the mobile device maker. His source said Microsoft has not yet approached Blackberry and is still in the "very early stages" of looking into making a potential deal, Harrington added. BlackBerry is up 1.7% to $10.50 following the blog post. Reference Link
14:54 EDTBBRYMicrosoft said to examine potential for BlackBerry bid, Betaville says
Subscribe for More Information
10:34 EDTBBRYOptions with increasing implied volatility
Subscribe for More Information
10:29 EDTDNDN, SNYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTPFE, BIIBAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use